Search Results

1 - 10 of 76 items :

  • "neoadjuvant chemotherapy" x
Clear All
Assessment of the Effect of Treatment with Neoadjuvant Chemotherapy on Breast Cancer Axillary Lymph Node

References 1. Bear HD. Indication for neoadjuvant chemotherapy for breast cancer. Semin Oncol. 1998; 25(2 Suppl3):3-12. 2. Botti C,Vici P, Lopez M, Scinto AF, Cognetti F, Cavaliere R. Prognotic value of lymph node metastasis after neoadjuvant chemotherapy for large-sized operable carcinoma of the breast. J Am CollSurg. 1995; 181 (3):202-208. 3. Kuerer HM, Newman LA, Buzdar AU, Hunt KK, Dhingra K, Buchholz TA, et al. Residual metastatic axillary lymph nodes following neoadjuvant chemotherapy predict disease

Open access
The role of neoadjuvant chemotherapy in patients with advanced (stage IIIC) epithelial ovarian cancer

, extensive peritonectomy, etc.) 2 , which increase morbidity of patients. Not all patients are candidates for primary surgery, either due to extend of their disease (unlikely to achieve no residual disease) or due to poor general condition (too ill to undergo an extensive operation). In this situation patients are treated with initial (neoadjuvant) chemotherapy, typically a combination of a platinum-based drug and a taxane. 3 Patients, who are treated with neoadjuvant chemotherapy, are more likely to undergo surgery with no residual disease than patients with primary

Open access
Diagnostic accuracy of MRI to evaluate tumour response and residual tumour size after neoadjuvant chemotherapy in breast cancer patients

Introduction Neoadjuvant chemotherapy (NAC) has been used in the management of large operable breast tumours with the purpose of modifying the surgical planning and increase the rate of breast conservative surgery (BCS). 1 – 6 Currently, NAC has been extended to selected patients with early-stage disease to improve the cosmetic outcome of BCS, especially in women with small breast size. 7 – 9 NAC has proved to be equivalent to postoperative chemotherapy in terms of disease-free and overall survival. 10 – 12 However, in the neoadjuvant setting, there is

Open access
Neoadjuvant chemotherapy in 13 patients with locally advanced poorly differentiated thyroid carcinoma based on Turin proposal - a single institution experience

. Insular carcinoma: a distinct thyroid carcinoma with associated iodine-131 localization. J Nucl Med 1991; 32: 1358-63. 12. Besic N, Auersperg M, Dremelj M, Vidergar-Kralj B, Gazic B. Neoadjuvant chemotherapy in 16 patients with locally advanced papillary thyroid carcinoma. Thyroid 2013; 23: 178-84. 13. Besic N, Auersperg M, Gazic B, Dremelj M, Zagar I. Neoadjuvant chemotherapy in 29 patients with locally advanced follicular or Hürthle cell thyroid carcinoma: a phase 2 study. Thyroid 2012; 22: 131-7. 14. Sobin LH, Gospodarowitz MK, Witekind

Open access
Primary debulking surgery versus primary neoadjuvant chemotherapy for high grade advanced stage ovarian cancer: comparison of survivals

in evaluating the feasibility of a successful PDS; at this regard recent prospective studies demonstrated a good accuracy of laparoscopic score in predicting residual disease after PDS. 7 However, randomized trials are mandatory to confirm these encouraging results. For patients in whom a complete cytoreduction during primary surgery is not expected, neoadjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS) is considered the most appropriate therapeutic option. 2 , 8 Recent studies demonstrated that such strategy allows higher rate of

Open access
Role of Percutaneous Needle Biopsy of Axillary Lymph Nodes to Evaluate Node Positive Breast Cancer after Neoadjuvant Chemotherapy

REFERENCES Akay, C. L., Albarracin, C., Torstenson, T., Bassett, R., Mittendorf, E. A., Yi, M., Kuerer, H. M., Babiera, G. V., Bedrosian, I., Hunt, K. K., Hwang, R. F. (2018). Factors impacting the accuracy of intra-operative evaluation of sentinel lymph nodes in breast cancer. Breast J. , 24 (1), 28–34. Baumgartner, A., Tausch, C., Hosch, S., Papassotiropoulos, B., Varga, Z., Rageth, C., Baege, A. (2018). Ultrasound-based prediction of pathologic response to neoadjuvant chemotherapy in breast cancer patients. Breast , 39 , 19–23. Boughey

Open access
Epirubicin and docetaxel as neoadjuvant treatment of hormone receptor positive, HER-2 negative breast cancer: findings from two successive phase II studies

days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group. J Clin Oncol 2005; 23: 2676-85. 11. Cheang MCU, Chia SK, Voduc D, Gao D, Leung S, Snider J, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 2009; 101: 736-50. 12. Kim SI, Sohn J, Koo JS, Park SH, Park HS, Park BW. Molecular subtypes and tumor response to neoadjuvant chemotherapy in patients with locally advanced breast cancer. Oncology 2010; 79: 324

Open access
Induction chemotherapy, chemoradiotherapy and consolidation chemotherapy in preoperative treatment of rectal cancer - long-term results of phase II OIGIT-01 Trial

-defined, high-risk, locally advanced rectal cancer treated with an intensified neoadjuvant strategy in the randomized phase 2 EXPERT-C Trial Int J Radiat Oncol 2015 93 303 12 10.1016/j.ijrobp.2015.03.038 17 Sclafani F, Brown G, Cunningham D, Wotherspoon A, Tait D, Peckitt C, et al. PAN-EX: a pooled analysis of two trials of neoadjuvant chemotherapy followed by chemoradiotherapy in MRI-defined, locally advanced rectal cancer. Ann Oncol 2016; 27 : 1557-65. 10.1093/annonc/mdw215 Sclafani F Brown G Cunningham D Wotherspoon A Tait D Peckitt C PAN-EX: a pooled analysis of two

Open access
Early complications after lung resections at patients treated for lung cancer with and without Neoadjuvant Hemiotheraphy

Chemotherapy Does Not Increase Complications After Nonsmall Cell Lung Cancer Resection. Ann Thorac Surg. 2005;80:423-427. 11. Martin J, Ginsberg RJ, Abolhoda A, Bains MS, Downey RJ, Korst RJ, Weigel TL, Kris MG, Venkatraman ES, Rusch VW. Morbidity and mortality after neoadjuvant therapy for lung cancer: the risks of right pneumonectomy. Ann Thorac Surg. 2001;72(4):1149-54. 12. Stolz AJ, Schützner J, Harustiak T, Lischke R, Simonek J, Pafko P. [Impact of neoadjuvant chemotherapy on postoperative complications following neumonectomy].Rozhl Chir

Open access
Tumor-Infiltrating Lymphocytes and Breast Cancer: Are Immune Checkpoint Inhibitors Ready for Prime Time in Breast Cancer?

-0539 17. Denkert C, Loibl S, Noske A et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 2010; 28: 105-13. http://dx.doi.org/10.1200/JCO.2009.23.7370 18. Apetoh L, Ghiringhelli F, Tesniere A et al. Tolllike receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007; 13: 1050-9. http://dx.doi.org/10.1038/nm1622 19. Desmedt C, Haibe-Kains B, Wirapati P et al. Biological processes associated with breast

Open access